title: Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis.
abstract: BACKGROUND
  Dabigatran is one of the three newer oral anticoagulants (OACs) recently approved in the United States for stroke prevention in non-valvular atrial fibrillation (NVAF) patients. The objective of this study was to identify patient, healthcare provider, and health plan factors associated with dabigatran versus warfarin use among NVAF patients.
  
  
  METHODS
  Administrative claims data from patients with ≥ 2 NVAF medical claims in the HealthCore Integrated Research Database between 10/1/2009 and 10/31/2011 were analyzed. During the study intake period (10/1/2010 - 10/31/2011), dabigatran patients had ≥ 2 dabigatran prescriptions, warfarin patients had ≥ 2 warfarin and no dabigatran prescriptions, and the first oral anticoagulant (OAC) prescription date was the index date. Continuous enrollment for 12 months preceding ("pre-index") and ≥ 6 months following the index date was required. Patients without pre-index warfarin use were assigned to the 'OAC-naïve' subgroup. Separate analyses were performed for 'all-patient' and 'OAC-naïve' cohorts. Multivariable logistic regression (LR) identified factors associated with dabigatran versus warfarin use.
  
  
  RESULTS
  Of 20,320 patients (3,019 dabigatran and 17,301 warfarin) who met study criteria, 27% of dabigatran and 13% of warfarin patients were OAC-naïve. Among all-patients, dabigatran patients were younger (mean 67 versus 73 years, p < 0.001), predominantly male (71% versus 61%, p < 0.001), and more frequently had a cardiologist prescriber (51% versus 30%, p < 0.001) than warfarin patients. Warfarin patients had higher pre-index Elixhauser Comorbidity Index (mean: 4.3 versus 4.0, p < 0.001) and higher ATRIA bleeding risk score (mean: 3.0 versus 2.3, p < 0.001). LR results were generally consistent between all- and OAC-naïve patients. Among OAC-naïve patients, strongest factors associated with dabigatran use were prescriber specialty (OR = 3.59, 95% CI 2.68-4.81 for cardiologist; OR = 2.22, 95% CI 1.65-2.97 for other specialist), health plan type (OR = 1.47 95% CI 1.10-1.96 for preferred provider organization), and prior ischemic stroke (OR = 1.42, 95% CI 1.06-1.90). Older age decreased the probability of dabigatran use.
  
  
  CONCLUSIONS
  Beside patient characteristics, cardiology specialty of the prescribing physician and health plan type were the strongest factors associated with dabigatran use.
authors.forename: Azza
authors.initials: A
authors.lastname: AbuDagga
authors.forename: Judith J
authors.initials: JJ
authors.lastname: Stephenson
authors.affiliation: HealthCore, Inc,, 800 Delaware Ave, 5th floor, Wilmington, DE 19801, USA. afu@healthcore.com.
authors.forename: An-Chen
authors.initials: AC
authors.lastname: Fu
authors.forename: Winghan Jacqueline
authors.initials: WJ
authors.lastname: Kwong
authors.forename: Hiangkiat
authors.initials: H
authors.lastname: Tan
authors.forename: William S
authors.initials: WS
authors.lastname: Weintraub
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001562:Benzimidazoles / Q000008:administration & dosage*; D015897:Comorbidity; D000069604:Dabigatran; D005260:Female; D006801:Humans; D007345:Insurance Claim Review; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D012306:Risk; D020521:Stroke / Q000517:prevention & control*; D014481:United States; D014859:Warfarin / Q000008:administration & dosage; D015091:beta-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran